v3.26.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2026
SEGMENT INFORMATION  
Schedule of Segment Information
b.Segment information:

Three Months Ended March 31, 

(U.S. dollars in thousands)

2026

2025

Revenues from customers

$

33,750

$

10,113

Less:

Employee salaries and related expenses

6,697

5,205

Sub-contractors expense

4,441

2,689

Interest expense

-

6

Interest income

(188)

(419)

Depreciation

404

346

Other segment expenses*

1,255

6,018

Income (loss) before taxes on income

21,141

(3,732)

Taxes on income (tax benefit)

2,824

(113)

Segment net income (loss)

$

18,317

$

(3,619)

* Other expenses included in net income include raw materials, rent and utilities, and others.

Schedule of Disaggregation of Revenues
c.The following table summarizes the Company’s disaggregation of revenues:

Three Months Ended March 31, 

(U.S. dollars in thousands)

2026

2025

  ​ ​ ​

Gaucher disease:

 

Pfizer (Ireland)

$

1,452

$

6,979

Fiocruz (Brazil)

$

2,454

$

3,016

Fabry disease:

Chiesi (Italy)

$

3,513

$

-

Total revenues from selling goods

$

7,419

$

9,995

Revenues from license and R&D services

$

26,331

$

118